Table 3.

HRs (95% CIs) estimated by multivariate COX regression with respect to OS in (a) the entire cohort, (B) cohort A and (C) cohort T; results of the backwards selection models

Parameter	Category	N events/ N patients	HR	95% CI	P value
A) Entire cohort
n=166 patients
Stage	Stage I-III	49/67	1 (Reference)
	Stage IV	93/99	2.48	1.73 to 3.56	< 0.001
KRAS/TP53 pathogenic mutations					< 0.001
	None	30/40	1 (Reference)
	Both KRAS&TP53	57/67	2.22	1.39 to 3.53	< 0.001
	Only KRAS	42/44	2.84	1.74 to 4.66	< 0.001
	Only TP53	13/15	1.67	0.87 to 3.23	0.13
B) Cohort A
n=138patients
KRAS/TP53 pathogenic mutations					< 0.001
	None	27/33	1(Reference)
	Both KRAS&TP53	48/54	2.12	1.30 to 3.47	0.003
	Only KRAS	36/38	3.17	1.88 to 5.37	< 0.001
	Only TP53	12/13	1.61	0.81 to 3.20	0.17
C) Cohort T
n=89 patients
KRAS/TP53 pathogenic mutations					0.002
	None	18/22	1 (Reference)
	Both KRAS and TP53	31/32	2.21	1.21 to 4.05	0.010
	Only KRAS	26/26	3.60	1.89 to 6.83	< 0.001
	Only TP53	9/9	2.16	0.96 to 4.87	0.063

N, number.